Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [9]. Core Views - The company is set to acquire Hunan Xingxin Aerospace New Materials Co., Ltd. through a cash transaction aimed at gaining control, with specific acquisition ratios to be determined through negotiations [4][5]. - Hunan Xingxin is a leader in aerospace thermal protection materials and has a strong focus on high-temperature resistant materials, with applications in major space missions [5]. - The acquisition is expected to create strategic synergies and enhance the company's market share in the aerospace and integrated equipment sectors, aiming to elevate its high-end cable integration and smart composite transmission business to world-class standards [5]. Summary by Sections Company Overview - Hunan Xingxin was established in 2003 and is recognized as a national high-tech enterprise, specializing in the development and production of high-temperature resistant materials and related products [5]. - The company reported revenues of 56.42 million yuan, 51.37 million yuan, and 68.15 million yuan for 2022, 2023, and 2024 respectively, with net profits of 23.63 million yuan, 22.46 million yuan, and 26.49 million yuan during the same period [5]. Market Dynamics - The report highlights the acceleration of satellite internet deployment in China, which is expected to significantly increase the demand for high-reliability, extreme-environment special cables [6][7]. - The company is well-positioned to benefit from the rapid development of the satellite internet sector, with its special cables being utilized in key projects such as the "Long March" series of rockets and the "Shenzhou" series of spacecraft [7]. Low-altitude Economy - The report discusses the establishment of a low-altitude economy development office by the government, which is expected to unlock significant airspace resources and create a market projected to reach 3.5 trillion yuan by 2035 [8]. - The company is poised to benefit from this development as a provincial state-owned enterprise, with its cable business expected to thrive in the low-altitude economy sector [8]. Financial Projections - Revenue forecasts for the company are projected at 39.94 billion yuan, 59.91 billion yuan, and 89.09 billion yuan for 2024, 2025, and 2026 respectively, with corresponding EPS of 0.22, 0.32, and 0.48 yuan [9][11]. - The company is expected to maintain a strong growth trajectory, benefiting from trends in low-orbit satellites and the low-altitude economy [9].

2025 年 03 月 25 日 双融日报 --鑫融讯 分析师：万蓉 S1050511020001 wanrong@cfsc.com.cn 市场情绪：38 分（较冷） 最近一年大盘走势 25 (%) 沪深300 资料来源：Wind，华鑫证券研究 -15 -10 -5 0 5 10 15 20 相关研究 1、《双融日报》2025-03-24 2、《双融日报》2025-03-21 3、《双融日报》2025-03-20 ▌ 华鑫市场情绪温度指标：（较冷） 华鑫市场情绪温度指标显示，昨日市场情绪综合评分为 38 分，市场情绪处于"较冷"。历史市场情绪趋势变化可参 考图表 1。 ▌ 热点主题追踪 今日热点主题：算力、家电、深海经济 宏观经济意外下滑、地缘不确定风险、流动性收紧超预期、 行业政策低于预期。 c 1、算力主题：据媒体报道，我国全面启动"东数西算" 工程已满 3 年，三大运营商、数据中心服务商以及相关产业 链企业积极跟进，多领域发力，各地新型数字基础设施加速 建设，全国一体化算力体系加快形成。据 2024 中国算力大会 数据，我国在用算力中心机架总规模超 830 万标准机架，算 力总规模达 246EFLOPS ...

Investment Rating - The report maintains a "Buy" recommendation for Horizon Robotics (9660.HK) [1] Core Insights - The automotive industry is experiencing rapid growth driven by favorable policies and high demand, creating an ideal market environment for Horizon Robotics. The deployment of urban NOA solutions and the expansion of highway NOA are contributing to the company's increasing market share and average selling price (ASP) [6][9] - In 2024, Horizon Robotics achieved record revenue of 2.384 billion yuan, a year-on-year increase of 53.6%, with a three-year compound growth rate of 72.19%. The gross profit reached 1.841 billion yuan, up 68.3% year-on-year, with a gross margin improvement from 70.88% in 2021 to 77.3% in 2024 [6][9] - The company holds over 40% market share in the ADAS market and has established partnerships with top global companies to promote autonomous driving solutions [7] Summary by Sections Industry Performance - The computer industry has shown varied performance over different time frames, with a 12-month increase of 21.4% [2] Market Performance - The report highlights the significant growth in the intelligent driving sector, with revenue from automotive solutions increasing by 57.2% year-on-year to 2.312 billion yuan in 2024 [9] Financial Highlights - Horizon Robotics' product delivery reached 2.9 million units in 2024, with cumulative deliveries of 7.7 million units. The company is set to scale production of the Horizon SuperDrive by Q3 2025 [7][9] Strategic Positioning - The company has built a technological moat through its integrated hardware and software solutions, with the J6M chip expected to capture over 50% market share [9] Future Outlook - The report anticipates continued strong growth for Horizon Robotics, driven by its leading position in the next-generation technology and the ongoing development of the global autonomous driving industry [10]

2025 年 03 月 24 日 业绩符合预期，产品结构优化 买入(维持) 事件 | 分析师：孙山山 | S1050521110005 | | --- | --- | | sunss@cfsc.com.cn | | | 联系人：肖燕南 | S1050123060024 | | xiaoyn@cfsc.com.cn | | | 基本数据 | 2025-03-21 | | --- | --- | | 当前股价（元） | 19.02 | | 总市值（亿元） | 96 | | 总股本（百万股） | 507 | | 流通股本（百万股） | 507 | | 52 周价格范围（元） | 15.59-23.55 | | 日均成交额（百万元） | 85.23 | 市场表现 3、《金徽酒（603919）：业绩高质 量增长，产品结构持续优化》2024- 04-20 —金徽酒（603919.SH）公司事件点评报告 2025 年 3 月 21 日，金徽酒发布 2024 年年报。 投资要点 -30 -20 -10 0 10 20 30 (%) 金徽酒 沪深300 资料来源：Wind，华鑫证券研究 相关研究 1、《金徽酒（603919）： ...

Investment Rating - The report maintains a "Buy" investment rating for the company [8]. Core Views - The company has turned its profit around, achieving a net profit of 1.46 billion yuan in 2024, compared to a loss of 0.66 billion yuan in 2023, despite a 12% decrease in revenue to 45.67 billion yuan [2]. - The company is focusing on brand cultivation and has seen a stabilization and recovery in its pig farming business, with a 3% increase in pig sales in early 2025 [3]. Summary by Sections Financial Performance - In 2024, the company reported a revenue of 45.67 billion yuan, down 12% year-on-year, primarily due to reduced pig sales from factory cleaning. The net profit was 1.46 billion yuan, a significant recovery from a loss of 0.66 billion yuan in 2023. The fourth quarter of 2024 saw a revenue of 10.92 billion yuan, a 13% decrease, with a net loss of 0.09 billion yuan [2]. - The gross margin improved by 8 percentage points to 20.87% in Q4 2024, driven by rising pig prices and falling wheat prices [2]. Business Strategy - The company is enhancing its product strategy, focusing on high-end soft and elastic noodle products, with a target to create a billion-yuan product in 2025. The revenue from instant food increased by 4% to 3.27 billion yuan in 2024 [3]. - The pig farming and slaughtering revenue decreased by 24% and 15% respectively, but early 2025 sales showed a recovery trend with 7.05 thousand pigs sold, a 3% increase [3]. Earnings Forecast - The company is expected to see earnings per share (EPS) of 0.48 yuan, 0.54 yuan, and 0.64 yuan for 2025, 2026, and 2027 respectively, with a projected net profit growth rate of 12.8% in 2025 [4][10]. - The forecasted revenue for 2025 is 46.57 billion yuan, reflecting a 2% growth from 2024 [10]. Market Position - The company is actively reforming its distribution channels to improve efficiency, focusing on direct consumer engagement and expanding into new market segments [3]. - The current stock price is 10.07 yuan, with a total market capitalization of 35 billion yuan [4].

2025 年 03 月 24 日 业绩短期承压，期待企稳回升 买入(维持) 事件 | 分析师：孙山山 | S1050521110005 | | --- | --- | | sunss@cfsc.com.cn | | | 联系人：肖燕南 | S1050123060024 | | xiaoyn@cfsc.com.cn | | | 基本数据 | 2025-03-21 | | --- | --- | | 当前股价（元） | 58.71 | | 总市值（亿元） | 196 | | 总股本（百万股） | 333 | | 流通股本（百万股） | 333 | | 52 周价格范围（元） | 40.18-82.9 | | 日均成交额（百万元） | 630.28 | 市场表现 -60 -40 -20 0 20 40 (%) 舍得酒业 沪深300 资料来源：Wind，华鑫证券研究 相关研究 1、《舍得酒业（600702）：调整期 业绩承压，发布回购方案彰显信 心》2024-10-29 2、《舍得酒业（600702）：利润不 及预期，短期去库释放压力》2024- 08-22 3、《舍得酒业（600702）：收入符 合预期，利润略承压 ...

Investment Rating - The report maintains a "Buy" investment rating for the company [1][8] Core Views - The company reported a slight revenue growth of 0.05% and a net profit increase of 23.12% for 2024, with revenues and net profits reaching 13.521 billion and 1.637 billion respectively [4] - The gross margin improved to 47.31%, up by 2.66 percentage points, attributed to increased production from self-owned factories and reduced raw material costs [4] - The beverage business saw significant growth, with revenue increasing by 30.80%, while packaged drinking water revenue declined by 2.59% [5] - The company is actively expanding its national presence and increasing the proportion of self-owned production, aiming for over 60% self-owned capacity by the end of the current five-year plan [6] Financial Performance Summary - For 2024, the company expects revenues of 13.521 billion, with projected growth rates of 6.8%, 7.5%, and 7.7% for the years 2025 to 2027 [10] - The earnings per share (EPS) are projected to be 0.84, 0.97, and 1.12 for 2025, 2026, and 2027 respectively, with corresponding price-to-earnings (P/E) ratios of 16, 14, and 12 [8][10] - The company’s return on equity (ROE) is expected to remain stable around 14.5% to 15.1% over the forecast period [10] Market Position and Strategy - The company is focusing on enhancing its distribution channels, with a 15% increase in retail coverage and over 20% growth in commercial refrigeration units [6] - New product launches and flavor innovations are driving the beverage segment, with a 122% increase in sales volume for a key product line [5][8] - The company is also investing in expanding production capacity, adding 22 new production lines, which includes 14 high-speed water lines and 3 sterile beverage lines [6]

Investment Rating - The report assigns a "Buy" rating for the company, marking the first coverage of the stock [9]. Core Views - The company experienced a revenue decline of 15.66% year-on-year in 2024, with total revenue reaching 1.861 billion yuan and a net profit of 340 million yuan, down 20.01% year-on-year [2][9]. - Despite short-term pressures in the coal industry, long-term resilience is expected due to policy support and increasing demand for intelligent mining solutions [2]. - The company is positioned as a leader in the unmanned intelligent mining control sector, benefiting from the ongoing industry upgrade trend [2][3]. Summary by Sections Industry Outlook - The coal industry is facing short-term challenges due to fluctuations in coal prices, but long-term demand is supported by capacity release and policy backing [2]. - The production of raw coal in China reached 4.76 billion tons in 2024, an increase of 1.3% year-on-year, marking a historical high [2]. Technology and Innovation - The company has established high technical barriers with 17 categories and 63 core technologies, including advancements in unmanned mining processes [3]. - R&D investment for 2024 is projected at 155 million yuan, representing 8.32% of revenue, with a focus on enhancing technological capabilities [7]. International Strategy - The company is expanding its international presence, achieving nearly 30 million yuan in overseas sales in 2024, a record high [8]. - Significant partnerships have been established with international clients, including a notable contract with a major Russian coal producer [8]. Financial Projections - Revenue forecasts for 2025-2027 are 1.822 billion yuan, 1.997 billion yuan, and 2.118 billion yuan, respectively, with expected EPS of 0.87, 0.98, and 1.08 yuan [9][11]. - The company anticipates a recovery in performance driven by international expansion and domestic policy support [9].

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [2][11]. Core Insights - New technology platforms are increasingly favored by multinational corporations (MNCs), leading to earlier collaboration opportunities. A notable example is the global strategic partnership between Heptares Therapeutics and AstraZeneca, which includes a $105 million equity investment [3]. - The weight loss market is seeing multiple business developments (BD) materialize, with significant sales growth reported by Novo Nordisk and Eli Lilly. Novo Nordisk's core products generated approximately $27.94 billion in sales, while Eli Lilly's tirzepatide saw a 124% year-on-year increase in sales to $11.54 billion [5]. - Progress in universal CAR-T and solid tumor cell therapies is ongoing, with global CAR-T sales projected at approximately $4.53 billion in 2024. Chinese companies are also participating in this market, with three domestic CAR-T products approved for sale [6]. - The CRO (Contract Research Organization) environment may experience changes, with potential supply flexibility due to the easing of U.S. bioterrorism law concerns. This could enhance the competitiveness of Chinese CROs [7]. - The active pharmaceutical ingredient (API) sector is exploring new applications, particularly in the nicotine tobacco production sector, leveraging synthetic biology technologies [8]. - Major hospitals are launching specialized AI models, indicating a rising trend in the integration of AI in healthcare, with collaborations between tech companies and healthcare providers [10]. Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 0.88 percentage points over the past week, ranking 20th among 31 primary industry indices [20]. 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical sector's index has a current PE (TTM) of 30.95, which is below the five-year historical average of 32.98 [36]. 3. Recent Research Achievements - The research team has published several in-depth reports on various pharmaceutical sectors, highlighting trends such as the growth of blood products and the impact of policy support on inhalation drug industries [40]. 4. Important Industry Policies and News - Recent policy changes include the National Medical Products Administration's (NMPA) decision to abolish certain medical device standards to optimize the regulatory framework [42]. - Significant industry news includes the approval of several new drug applications and clinical trials by the NMPA, indicating a robust pipeline for pharmaceutical innovation [44][46].

2025 年 03 月 22 日 研 究 报 告 背靠施耐德拓展数据中心业务，厦门国资入主助 力公司新成长 买入(首次) 事件 | 分析师：任春阳 | S1050521110006 | | --- | --- | | rency@cfsc.com.cn | | | 分析师：傅鸿浩 | S1050521120004 | | fuhh@cfsc.com.cn | | | 分析师：杜飞 | S1050523070001 | | dufei2@cfsc.com.cn | | | 基本数据 | 2025-03-21 | | --- | --- | | 当前股价（元） | 14.45 | | 总市值（亿元） | 48 | | 总股本（百万股） | 333 | | 流通股本（百万股） | 255 | | 52 周价格范围（元） | 9.05-17.42 | | 日均成交额（百万元） | 152.35 | 市场表现 —电工合金（300697.SZ）公司事件点评报告 3 月 21 日晚公司发布 2024 年报：报告期内公司实现营收 25.93 亿元，同比增长 8.37%，实现归母净利润 1.31 亿元， 同比下降 3.62%。 ...